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Abstract: Hundreds of million people worldwide have been infected with severe acute 
  respiratory syndrome (SARS), and the rate of global death from SARS has remarkably 
increased. Hence, the development of efficient drug treatments for the biological effects of 
SARS is highly needed. We have previously shown that quantum dots (QDs)-conjugated RNA 
oligonucleotide is   sensitive to the specific recognition of the SARS-associated coronavirus 
(SARS-CoV)   nucleocapsid (N) protein. In this study, we found that a designed biochip could 
analyze inhibitors of the SARS-CoV N protein using nanoparticle-based RNA oligonucleotide. 
Among the polyphenolic   compounds examined, (-)-catechin gallate and (-)-gallocatechin gallate 
demonstrated a remarkable inhibition activity on SARS-CoV N protein. (-)-catechin gallate and 
(-)-gallocatechin gallate attenuated the binding affinity in a concentrated manner as evidenced by 
QDs-conjugated RNA oligonucleotide on a designed biochip. At a concentration of 0.05 µg mL–1, 
(-)-catechin gallate and (-)-gallocatechin gallate showed more than 40% inhibition activity on 
a nanoparticle-based RNA oligonucleotide biochip system.
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Introduction
Severe acute respiratory syndrome (SARS) is an infectious disease that began in 
  Guandong, China in November 2002. It has caused serious infections in many nations, 
such as Asia, Europe and Canada.1–6 According to the World Health Organization 
(WHO), the mortality of patients afflicted with SARS is 15% on average and 50% or 
higher in patients aged 65 years and over.7 SARS-associated coronavirus (SARS-CoV) 
is an enveloped and positively single-stranded RNA virus with a typical genome size of 
29.7 kb. It encodes RNA-directed RNA polymerase and structural proteins, including the 
spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.8–11 The N protein 
is a 422 amino acids alkaline protein with a short lysine-rich region suggested as the 
nuclear localization signal. It plays an important role in the process of virus particle 
assembly by enveloping the entire genomic RNA.12 The SARS-CoV N protein is a major 
pathological determinant in the host and might cause host cell apoptosis, upregulate the 
proinflammatory cytokine production, and block innate immune responses. Moreover, 
the N protein of the SARS-CoV is an important antigen for both the early diagnosis 
of SARS and the detection of diseases.13 Since SARS broke out in 2003, researchers 
have made great efforts to develop fast and accurate analytical methods for its early 
diagnosis.14–18 In addition, due to its essential role in SARS replication, the SARS-CoV N 
protein is mainly regarded as a prime target for anti-SARS therapy. For this reason, 
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the SARS-CoV N protein is an attractive and crucial target 
for anti-SARS therapeutic drug discovery.
Polyphenolic compounds are phytochemicals found in 
numerous plants and fruits.19–21 They have been reported to 
act as antioxidants, free radical scavengers, metal chelators, 
and to be antiallergic, anticancer, antioxidant, anti-inflam-
matory, antifungal, and antiviral and antibacterial agents. In 
general, these polyphenolic compounds are known to have 
medicinal and chemopreventive activity in human health.22–25 
In particular, (-)-catechin gallate and (-)-  gallocatechin gal-
late are known as a type of catechin. (-)-Catechin gallate and 
(-)-gallocatechin gallate are the most abundant catechins, 
particularly in tea and other plants, and they are a potent 
antioxidants26 with possible therapeutic properties for many 
disorders, including cancer.27,28 Researchers reported the 
benefit of catechin gallate from green tea in the treatment 
of human immunodeficiency virus (HIV) infection, where 
(-)-catechin gallate has been shown to reduce plaques 
related to acquired immunodeficiency syndrome-related 
dementia.29,30 There have also been reports showing that cat-
echin gallate can be beneficial in treating brain,31 prostate,32 
and other types of cancers.33
In this study, we report a novel approach for the inhibi-
tor screening of SARS-CoV N protein using a quantum 
dots (QDs)-conjugated oligonucleotide system with wide 
applicability for facile and sensitive imaging analysis on a 
biochip. We elucidated the inhibitor on SARS-CoV N protein 
identified through a high-throughput screening strategy using 
an optical nanoparticle-based RNA oligonucleotide. To the 
best of our knowledge, this is the first report on the inhibition 
effects of (-)-catechin gallate and (-)-gallocatechin gallate on 
SARS-CoV N protein using an optical nanoparticle-based 
RNA oligonucleotide platform.
Materials and methods
Chemicals
EDC (N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride), bovine serum albumin (BSA), ampicillin, 
kanamycin, (-)-catechin gallate, (-)-gallocatechin gallate, and 
other molecules were purchased from Sigma-Aldrich Chemical 
Co (St Louis, MO). Quantum dots (QD605) were purchased 
from Invitrogen (Carlsbad, CA). ProlinkerTM-terminated glass 
slides from Proteogen (Seoul, Republic of Korea) were used. 
All other chemicals were of the highest grade.
Preparation of RNA oligonucleotide
The production of designed RNA oligonucleotide and 
primer with T7 promoter sequence were synthesized by 
Bioneer Co Ltd (Seoul, Republic of Korea) and amplified 
by   polymerase chain reaction (PCR). Template RNA was 
prepared by in vitro transcription using T7 RNA polymerase 
(Promega, Madison, WI). All RNA transcript products were 
separated by 8 M Urea 6% polyacrylamide gel electrophoresis 
(PAGE) after phenol extraction and ethanol precipitation pro-
cedures. The produced RNA oligonucleotide was solved in 
0.1% diethylpyrocarbonate (DEPC) solution and stored at 
-70°C for further experiments.
Subcloning, expression, and purification  
of SARS-CoV N protein
The gene was amplified by a PCR with the primer set in the direc-
tion of sense at 5′-agtggatccatgtctgataatggacccca-3′ and in the 
direction of antisense at 5′-gccgtcgacttatgcctgagttgaatcagc-3′, 
containing restriction enzyme sites of BamHI/SalI. PCR 
was run with the following conditions on a thermal cycler: 
denaturation at 94°C for 1 minute; annealing at 60°C for 
30 seconds; and an extension step at 72°C for 2.5 min-
utes. The sequence was repeated 35 times and   followed 
by a 7 minute final extension step at 72°C. The PCR 
product was digested with BamHI/SalI, and then ligated into 
BamHI/SalI digested expression vector pET 24a+ (Novagen, 
Madison, WI), and transformed into Escherichia coli DH5α 
(Stratagene, La Jolla, CA). The colony with insert gene 
was transformed into E. coli BL21 (DE3) (Stratagene). It 
was then plated on Luria–Bertani (LB) agar containing 
50 µg mL–1 kanamycin. GroES/EL expressing plasmid 
from E. coli and SARS-CoV N-expressing plasmid, which 
possessed ampicillin- and kanamycin-resistant markers, 
were cotransformed into E. coli BL21 (DE3) according 
to biotransformation procedures. The transformant was 
grown in a 250 mL flask containing 50 mL LB medium 
supplemented by 50 µg mL–1 of kanamycin and ampicillin 
at 37°C until the cell concentration reached OD600 nm of 0.6 
and isopropyl-thio-β-D-galactopyranoside (IPTG) of a final 
concentration of 0.1 mM. It then was left to grow overnight 
at 25°C with shaking. The cells were harvested by centrifu-
gation at 4000 rpm for 30 minutes at 4°C and resuspended 
in 100 mM potassium phosphate-buffered saline (pH 7.5) 
containing 1 mM phenylmethylsulfonyl fluoride (PMSF). 
The cells were lysed by Sonicator® (F60 Sonic Dismembra-
tor; Fisher Scientific, Fair Lawn, NJ). The cell debris was 
removed by centrifugation at 13,000 rpm for 30 minutes. The 
supernatant was collected and the recombinant SARS-CoV N 
protein was purified with Ni-nitrilotriacetic acid (Ni-NTA) 
affinity   chromatography column (Qiagen, Germany). The 
supernatant was equilibrated with buffer A (10 mM Tri-HCl, 
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Figure 1 A representative scheme for the inhibitor screening of SARS-CoV N protein using QDs-conjugated RNA oligonucleotide on biochip.
Abbreviations: N, nucleocapsid; SARS-CoV, severe acute respiratory syndrome-associated coronavirus; QDs, quantum dots.
500 mM NaCl, 50 mM imidazole, 1 mM PMSF, pH 8.0). The 
bound protein was eluted with buffer B (10 mM   Tris-HCl, 
500 mM NaCl, 250 mM imidazole, 1 mM PMSF, pH 8.0) 
at 4°C. The purity of the purified protein was estimated by 
sodium dodecyl sulfate (SDS)-PAGE in the eluted fractions 
using 12% polyacrylamide running gels.34 The purity of the 
enzyme was estimated by SDS-PAGE. The protein concentra-
tion was determined as described by the Bradford method.35 
The purified sample was supplemented with 50% glycerol 
and stored at -20°C until use.
Conjugation of QDs and RNA 
oligonucleotide
The amine group of RNA oligonucleotide was first covalently 
conjugated onto the surface of the carboxyl terminated QD605 
(10 pM). That is, 10 pM of QD605 were conjugated with 
400 pM of RNA oligonucleotide with the coupling reagent 
EDC (N-(3-dimethylaminopropyl)-N-ethyl-carbodiimide 
hydrochloride, 40 nM), which was used to activate an 
amide bond formation to produce QDs-conjugated RNA 
  oligonucleotide (QDs-based SARS-CoV N RNA oligonucle-
otide) at a QDs:RNA oligonucleotide molar ratio of 1:40 
for 1 hour at room temperature. QDs-RNA oligonucleotide 
conjugate was then collected using centrifugal filtration at 
15 000 rpm for 30 minutes followed by several washing 
steps with a Tris buffer (50 mM Tris-HCl [pH 7.4], 5 mM 
KCl, 100 mM NaCl, 1 mM MgCl2, and 0.1% NaN3). After 
centrifugal filtration and washing, the pellet of QDs-RNA 
oligonucleotide was dispersed by brief sonication (22 kHz, 
amplitude 12 µm, and sonication time 120 seconds) using a 
sonic dismembrator model F60 (Fisher Scientific).
Fluorescent assay in a confocal  
laser-scanning microscope
The recombinant SARS-CoV N protein was directly immo-
bilized onto the functional ProLinkerTM-terminated surface. 
For the binding of the specific RNA oligonucleotide, the 
conjugated QDs-conjugated RNA oligonucleotide was facili-
tated by spotting on an immobilized SARS-CoV N protein 
chip. Subsequently, the polyphenolic compound used as 
inhibitor was spotted on the conjugated RNA   oligonucleotide 
and the SARS-CoV N protein. After incubation for 1 hour 
at 25°C, the chip was then washed three times with 
  phosphate-buffered saline (pH 7.2) for 1 minute. The chip 
was analyzed by a confocal laser scanning microscope LSM 
510 META (Carl Zeiss, Jena, Germany). The signal intensity 
was   determined by software for the LSM 510 (LSM Image 
Browser; Carl Zeiss). A histogram of the intensity was 
achieved from the region of the spotted chip. The value of 
signal intensity was achieved by calculating and expressing 
it as the mean intensity.
Results and discussion
Scheme for inhibitor screening  
of SARS-CoV N protein on chip
For the inhibitor screening of the SARS-CoV N protein, 
we designed the QDs-conjugated specific RNA oligonucle-
otide for specific SARS-CoV N protein targeting: first, the 
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Table 1 The effects of polyphenolic compounds on the inhibition 
of SARS-CoV N protein used in this study
Compounds Inhibition activity
Quercetin –
Acacetin –
Apigenin –
Baicalein –
hesperidin –
Morin –
Rutin –
Naringin –
Naringenin –
(-)-Catechin –
(-)-Catechin gallate +
(-)-gallocatechin gallate +
Diosmin –
Daidzein –
genistein –
glycitein –
Kaempferol –
Luteolin –
Myricetin –
Silibinin –
Silymarin –
Orientin –
Oroxylin A –
Notes:  +  indicates  inhibition  activity  on  SARS-CoV  N  protein;  –  indicates  no 
inhibition activity on SARS-CoV N protein.
Abbreviations: N, nucleocapsid; SARS-CoV, severe acute respiratory syndrome-
associated coronavirus.
SARS-CoV N protein (1 µL) was immobilized on a glass 
chip; second, QDs-conjugated RNA oligonucleotide con-
jugates (1 µL) were bound on an immobilized chip; third, 
inhibitor treatment was performed on the conjugated RNA 
oligonucleotide and SARS-CoV N protein; fourth, washing 
and unspecific binding removal was done; fifth, detection 
was achieved to show directly the specific recognition of 
the inhibition effect of SARS-CoV N protein on the biochip. 
The schematic design of the inhibitor screening for effective 
monitoring of SARS-CoV N protein is illustrated in Figure 1. 
To accomplish the feasibility of targeting and imaging, we 
used QD605 conjugates having an RNA oligonucleotide for 
SARS-CoV N protein with an emission wavelength as the 
optical imaging probe.
Secondary structure of RNA 
oligonucleotide and expression  
and purification of SARS-CoV N protein
Figure 2A presents the secondary structure of RNA oligonu-
cleotide that binds to SARS-CoV N protein. The RNA second-
ary structure of the used RNA oligonucleotide was analyzed 
using the Mfold program.36 In order to improve the solubility 
of the overexpressed recombinant SARS-CoV N protein, the 
coexpression of N protein with E. coli molecular chaperone 
GroES/EL was performed. The SARS-CoV N protein was 
purified by a single chromatography step on a Ni2+ affinity 
column. The C-terminal his-tagged SARS-CoV N protein was 
visualized with a molecular mass of approximately 48 kDa 
on a SDS-PAGE (Figure 2B). The sequence is 5′-gggagagcg-
gaagcgugcugggccugucgguucgcugucuugcuacguuacguuacacg-
guuggcauaacccagaggucgauggaucccccc-3′.
Quantum dots (QDs)-conjugated  
RNA oligonucleotide
The QDs-supported RNA oligonucleotide was conjugated 
in the reaction for the amide formation from the coupling of 
5′-end-amine-modified RNA oligonucleotide at the   surface of 
QDs displaying carboxyl groups via standard EDC coupling. 
60
40
M1 23 4
AB
Figure 2 (A) Sequence and secondary structure of RNA oligonucleotide that binds to N protein. (B) Purification of SARS-CoV N protein, 12% SDS-PAGE gel showing 
SARS-CoV N protein with his-tag. M, protein marker; lane 1, before induction form of SARS-CoV N protein; lane 2, total form of SARS-CoV N protein; lane 3, soluble form 
of SARS-CoV N protein; lane 4, his-tag form of SARS-CoV N protein.
Abbreviations:  N,  nucleocapsid;  SARS-CoV,  severe  acute  respiratory  syndrome-associated  coronavirus;  SDS-PAgE,  sodium  dodecyl  sulphate-polyacrylamide 
gel electrophoresis; QDs, quantum dots.
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Figure 3 Chemical structures of (A) (-)-catechin gallate and (B) (-)-gallocatechin 
gallate.
The QDs-conjugated RNA   oligonucleotide was confirmed 
on a 2.5% agarose gel at 100 V in TAE buffer. Agarose 
gel electrophoresis showed a band with mobility having a 
different band pattern between the free QDs and the QDs-
conjugated RNA oligonucleotide, which confirmed the 
formation of QDs-conjugated RNA oligonucleotide. The 
mobility shifts were compared (data not shown). On agarose 
gel, the QDs-conjugated RNA oligonucleotide showed a 
lower mobility shift than free QDs, thus demonstrating the 
amide formation between QDs and RNA oligonucleotide 
for conjugation.
Inhibitory effect of SARS-CoV 
N protein
In Table 1, the effects of polyphenolic compounds on the 
inhibition of the SARS-CoV N protein used in this study are 
described. Among the polyphenolic compounds screened, 
(-)-catechin gallate and (-)-gallocatechin gallate showed 
high anti-SARS-CoV N protein activity. The chemical 
structures of (-)-catechin gallate and (-)-gallocatechin gal-
late are shown in Figure 3. Figure 4 shows our   elucidation 
of (-)-catechin gallate; (-)-gallocatechin gallate showed 
high inhibition activity in a concentrated manner against 
SARS-CoV N protein. (-)-catechin gallate and (-)-gallo-
catechin gallate, at 0.005 µg mL–1 or more, concentration-
dependently attenuated the binding affinity as evidenced 
by QDs-RNA oligonucleotide on the designed biochip 
(Figure 4A and B). At a concentration of 0.05 µg mL–1, 
(-)-catechin gallate and (-)-gallocatechin gallate showed 
more than 40% inhibition activity on a QDs-RNA oli-
gonucleotide biochip platform. As shown in Figure 4A 
and B, (-)-catechin gallate and (-)-gallocatechin gal-
late showed a similar pattern when comparing the 
  concentration-dependent anti-SARS activity. The 
half-maximal inhibitory concentration (IC50) values of 
(-)-catechin gallate and (-)-gallocatechin gallate were found 
to be approximately 0.05 µg mL–1, respectively (Figure 4A 
and B). Other polyphenolic compounds to the inhibition 
of SARS-CoV N protein on the nanoparticle-based RNA 
oligonucleotide biochip system were detected as nearly 
similar to the background signal, due to the high affinity 
with the QDs-conjugated aptamer-SARS-CoV N protein 
(data not shown). To perform high-throughput screening of 
the inhibitors, it would be efficient to be able to measure the 
anti-SARS activity from optical images of a biochip con-
taining multiple reaction compounds. To demonstrate the 
feasibility of the inhibitor assays, the latter were carried out 
on a biochip within 60 minutes at 37°C, and optical images 
were obtained from the reaction mixtures on a plate using a 
QDs-based imaging system. The inhibition of the anti-SARS 
activity from (-)-catechin gallate and (-)-gallocatechin 
gallate were clearly illustrated, and dose dependency 
was distinctly observable in the optical images.
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Figure 4 Inhibitory effect of (A) (-)-catechin gallate and (B) (-)-gallocatechin gallate to SARS-CoV N protein.
Abbreviations: N, nucleocapsid; SARS-CoV, severe acute respiratory syndrome-associated coronavirus.
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Conclusion
We demonstrated inhibitor screening on a biochip plat-
form using a QDs-conjugated RNA oligonucleotide. We 
discovered a novel function of (-)-catechin gallate and 
(-)-gallocatechin gallate as anti-SARS agents. The discov-
ery of anti-SARS agents has been of considerable interest 
in developing an efficient and effective methodology for 
high-throughput screening. Our main goal in this study is to 
demonstrate a proof-of-concept that SARS-CoV N protein 
can be inhibited and detected with remarkable simplicity 
and speed. Regarding its application, this designed platform 
for a novel inhibitor assay possesses significant potential as 
a target screening. In particular, it is a promising method 
for inhibitor screening because of its high sensitivity, low 
cost, rapid response, compatibility for miniaturization, and 
low labor-intensity. In addition, this platform is expected 
to be applicable to the inhibitor screening of other types of 
diseases.
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